Cidara Therapeutics Profit Margin 2014-2022 | CDTX
Current and historical gross margin, operating margin and net profit margin for Cidara Therapeutics (CDTX) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Cidara Therapeutics net profit margin as of September 30, 2022 is -54.21%.
| Cidara Therapeutics Annual Profit Margins |
| Cidara Therapeutics Quarterly Profit Margins |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.087B |
$0.050B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
